glp-1 drugs competitive intelligence 2025 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes GLP-1 Receptor Agonist Market Size

The most commonly reported adverse events were gastrointestinal, including: Nausea Vomiting Diarrhea GI discomfort Higher doses generally produced stronger effects but also higher dropout rates

doi: 10.3389/fphar.2021.674366 53 DongZLiRXuLXinKXuYShiHet al

These GLP-1 receptor agonists can be categorized as either short-acting compounds, which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compounds (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose

They smooth lines already formed by years of muscle contraction and prevent them from deepening